April 9, 2024
View Full PaperSafety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.007)
Key Points
Key points are not available for this paper at this time.
Abstract
This first-in-human phase 1 study assesses the safety, tolerability, and clinical outcomes of bemdaneprocel in participants with Parkinson's disease.